AbbVie

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.

AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.

AbbVie Gains as Qulipta Opens a New Migraine Market

The Phase 3 victory supports intermittent treatment, potentially expanding use without requiring continuous daily dosing.

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next

AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide (CGRP) r…

AbbVie's (ABBV) Botox Just Got A Step Closer To A Fifth Use

AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands.

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

The stock is up just 8% this year and could prove to be an undervalued buy.

Franklin Street Advisors Inc. NC Has $45.71 Million Stock Holdings in AbbVie Inc. $ABBV

Franklin Street Advisors Inc. NC boosted its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 1.4% during the 2nd quarter, according to its most recent dis…

Sax Wealth Advisors LLC Raises Stock Holdings in AbbVie Inc. $ABBV

Sax Wealth Advisors LLC increased its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 24.8% during the second quarter, according to its most recent filing…

Oliver Luxxe Assets LLC Lowers Stock Position in AbbVie Inc. $ABBV

Oliver Luxxe Assets LLC lowered its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 6.4% during the 2nd quarter, according to its most recent di…

Research Analysts' Price Target Changes for August 3rd (ABBV, ABR, ACGL, ADP, AEE, AEM, AEP, AGM, AJG, ALNY)

Research Analysts' price target changes for Monday, August 3rd: AbbVie (NYSE:ABBV) had its target price raised by Cantor Fitzgerald from $265.00 to $285.00. Th…

Investors are overlooking healthcare stocks and should consider these top picks, says JPMorgan

Eli Lilly, AbbVie and Danaher Corporation are among the bank's top picks for stocks in the sector.

Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?

AbbVie (NYSE:ABBV) Given New $265.00 Price Target at Cantor Fitzgerald

AbbVie (NYSE:ABBV - Get Free Report) had its target price boosted by analysts at Cantor Fitzgerald from $240.00 to $265.00 in a research report issued to clien…

The Zacks Analyst Blog Highlights Applied Materials, Mastercard, AbbVie, INNOVATE and BranchOut

AMAT, MA, ABBV, VATE and BOF headline new research reports highlighting AI, payments, healthcare and microcap growth opportunities.

Best Pharmaceutical Stocks To Follow Today - July 5th

Eli Lilly and Company, AbbVie, and Pfizer are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical sto…

Research Analysts' Downgrades for July 5th (ABBV, ACR, ALB, APOG, AUNA, BIAF, BIRK, CARE, CDLR, CMP)

Research Analysts' downgrades for Sunday, July 5th: AbbVie (NYSE:ABBV) was downgraded by analysts at Wall Street Zen from a strong-buy rating to a buy rating.…

Expanding RINVOQ And SKYRIZI Uses Might Change The Case For Investing In AbbVie (ABBV)

In late June 2026, AbbVie reported multiple product wins, including new pediatric approvals for SKYRIZI, positive CHMP opinions for RINVOQ in alopecia areata a…

Hudson Edge Investment Partners Inc. Has $7.12 Million Holdings in AbbVie Inc. $ABBV

Hudson Edge Investment Partners Inc. increased its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 7.2% during the first quarter, Holdings Channel reports…

(ABBV) and the Role of Price-Sensitive Allocations

Price-action only: Abbvie Inc. (ABBV) movements set the tone for institutional models. (ABBV) and the Role of Price-Sensitive Allocations

Equities Research Analysts' Upgrades for June 27th (AADX, ABBV, ABSI, ACR, AEIS, AEM, AERO, AFCG, AIRS, AKTX)

Equities Research Analysts' upgrades for Saturday, June 27th: Applied Aerospace & Defense (NYSE:AADX) was upgraded by analysts at Wall Street Zen from a sell r…

Healthcare stocks have become a haven for investors ditching tech

Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceut…

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.

AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push

AbbVie said on Monday it would buy biotech Apogee ⁠Therapeutics for $10.9 billion, in more than five years.

AbbVie would gain an experimental eczema drug by buying biotech: report

AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial…

How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?

ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.

Stonebridge Financial Group LLC MO Acquires New Stake in AbbVie Inc. $ABBV

Stonebridge Financial Group LLC MO acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) in the fourth quarter, HoldingsChannel.com reports.…

The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio

Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term

AbbVie Inc. (NYSE:ABBV) is one of the best healthcare stocks to buy for the long term. AbbVie Inc.